Drugs / ganagliflozin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07116928 | Nov 2025 → Oct 2031 expected | chronic kidney disease, type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07244003 | Mar 2025 → Dec 2027 expected | type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ganagliflozin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07244003 ↗ |
| Route | Oral | “Ganagliflozin tablet : 50mg/d.” NCT07244003 ↗ |